title: Hemodynamic evaluation of octreotide in patients with hepatitis B-related cirrhosis.
abstract: The hemodynamic effects of octreotide were studied in 20 patients with hepatitis B-related cirrhosis. In patients receiving a 100-micrograms bolus and a 100-micrograms/h infusion, heart rate, cardiac index, and systemic vascular resistance showed no significant changes, whereas right atrial pressure, pulmonary capillary wedge pressure, and inferior vena cava pressure decreased significantly after octreotide infusion compared with basal values. In contrast, in patients receiving a 50-micrograms bolus and a 50-micrograms/h infusion, all the systemic hemodynamic values were unaffected. In both groups of patients receiving two different doses of octreotide, the estimated hepatic blood flow, hepatic indocyanine green clearance, and wedge hepatic venous pressure were significantly reduced at 60 minutes after octreotide administration compared with basal values, whereas the hepatic venous pressure gradient remained unchanged. It is concluded that the two different doses of octreotide administration result in the reduction of the wedge hepatic venous pressure and the hepatic blood flow of a similar magnitude, whereas the hepatic venous pressure gradient is unaffected. Octreotide induces discrepant systemic hemodynamic response; this effect is dose related.
authors.affiliation: Department of Medicine, Taipei Veterans General Hospital, Taiwan.
authors.forename: H C
authors.initials: HC
authors.lastname: Lin
authors.forename: Y T
authors.initials: YT
authors.lastname: Tsai
authors.forename: F Y
authors.initials: FY
authors.lastname: Lee
authors.forename: S D
authors.initials: SD
authors.lastname: Lee
authors.forename: H C
authors.initials: HC
authors.lastname: Hsia
authors.forename: W J
authors.initials: WJ
authors.lastname: Lin
authors.forename: K J
authors.initials: KJ
authors.lastname: Lo
mesh_terms: D006439:Hemodynamics / Q000187:drug effects*; D006509:Hepatitis B / Q000150:complications*; D006801:Humans; D006975:Hypertension, Portal / Q000503:physiopathology; D008102:Liver Circulation / Q000187:drug effects; D008103:Liver Cirrhosis / Q000209:etiology / Q000503:physiopathology*; D015282:Octreotide / Q000494:pharmacology*
chemical_list: D015282:Octreotide